RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened Rhythm Pharmaceuticals, Inc. (RYTM) filed an 8-K reporting the results of its Annual Meeting of Stockholders held on June 24, 2026. Two Class III directors — David W. J. McGirr and David P. Meeker, MD — were elected to serve until the 2029 annual meeting. The company reported 68,530,107 common shares outstanding as of the April 27, 2026 record date and 115,000 shares of Series A convertible preferred stock (55,000 of which were voting), yielding 69,675,938 total eligible votes; about 64,146,146 votes (≈92%) were represented at the meeting.

Key Details

• Record date: April 27, 2026; Meeting date: June 24, 2026; Form 8-K signed June 25, 2026 by CFO Hunter Smith.
• Director election votes:
  • David W. J. McGirr: 53,167,971 FOR; 8,704,527 WITHHELD; 2,273,648 broker non-votes.
  • David P. Meeker, MD: 59,961,848 FOR; 1,910,650 WITHHELD; 2,273,648 broker non-votes.
• Series A preferred voting conversion: 20.8333 votes per $1,000 liquidation preference = 1,145,831 total votes from voting preferred shares.
• Auditor ratification (Item 2): Ernst & Young LLP reappointed — 63,924,852 FOR; 197,701 AGAINST; 23,593 ABSTAINED.
• Advisory vote on executive compensation (Item 3): Approved — 50,368,659 FOR; 11,467,157 AGAINST; 36,682 ABSTAINED; 2,273,648 broker non-votes.

Why It Matters The filing confirms the company’s board makeup for the next term (two Class III directors elected) and reaffirms Ernst & Young LLP as the independent auditor — both are governance items investors monitor for continuity and oversight. The advisory (non-binding) approval of executive compensation indicates a majority shareholder endorsement of pay practices but does not change contracts by itself. High vote participation (~92%) and the presence of broker non-votes from the Series A preferred stock are notable for understanding shareholder engagement and voting dynamics.